经尿道整块切除与标准膀胱肿瘤电切术的随机多中心3期试验
这项在中国香港开展的多中心随机3期试验纳入膀胱肿瘤≤3cm的成人患者,比较经尿道膀胱肿瘤整块切除(ERBT)与标准电切(SR)的1年复发率。在276例组织学确诊的非肌层浸润性膀胱癌(NMIBC)患者中,ERBT组1年复发率为29%,SR组为38%,差异有统计学意义(p=0.007)。
要点
- ERBT组1年复发率为29%(95%CI 18-37),SR组为38%(95%CI 28-46),p=0.007。
- ERBT组1年进展率为0%,SR组为2.6%(95%CI 0-5.5),p=0.065。
- ERBT组中位手术时间为28分钟(IQR 20-45),SR组为22分钟(IQR 15-30),p<0.001。
核心结论
- 对于≤3cm的NMIBC患者,与SR相比,ERBT显著降低了1年复发率。
- 研究结果支持将ERBT作为≤3cm膀胱肿瘤患者的一线手术治疗。
研究设计与样本
- 在中国香港开展的多中心、随机、3期试验。
- 2017年4月至2020年12月纳入膀胱肿瘤≤3cm的成人患者,随访至术后1年。
- 患者按1:1比例随机分配接受ERBT或SR。
- 主要结局为1年复发率,对组织学确诊NMIBC的患者进行改良意向性治疗分析。
主要发现
- 共350例患者随机分组,其中276例组织学确诊为NMIBC。
- 1年时,ERBT组31例、SR组46例出现复发;Kaplan-Meier估计1年复发率ERBT组为29%(95%CI 18-37),SR组为38%(95%CI 28-46),p=0.007。
- 亚组分析中,肿瘤1-3cm、单发肿瘤、Ta期或中危NMIBC患者从ERBT中显著获益。
- ERBT组无患者、SR组3例患者进展为肌层浸润性膀胱癌;Kaplan-Meier估计1年进展率ERBT组为0%,SR组为2.6%(95%CI 0-5.5),p=0.065。
- 中位手术时间ERBT组为28分钟(IQR 20-45),SR组为22分钟(IQR 15-30),p<0.001。
临床怎么用
- 作者结论认为,在≤3cm的NMIBC患者中,与SR相比ERBT显著降低1年复发率。
- 作者认为研究结果支持ERBT作为≤3cm膀胱肿瘤患者的一线手术治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Conventionally, standard resection (SR) is performed by resecting the bladder tumour in a piecemeal manner. En bloc resection of the bladder tumour (ERBT) has been proposed as an alternative technique in treating non-muscle-invasive bladder cancer (NMIBC). The objective of this study is to investigate whether ERBT could improve the 1-yr recurrence rate of NMIBC, as compared with SR. METHODS: A multicentre, randomised, phase 3 trial was conducted in Hong Kong. Adults with bladder tumour(s) of ≤ 3cm were enrolled from April 2017 to December 2020, and followed up until 1 yr after surgery. Patients were randomly assigned to receive either ERBT or SR in a 1:1 ratio. The primary outcome was 1-yr recurrence rate. A modified intention-to-treat analysis on patients with histologically confirmed NMIBC was performed. The main secondary outcomes included detrusor muscle sampling rate, operative time, hospital stay, 30-d complications, any residual or upstaging of disease upon second-look transurethral resection, and 1-yr progression rate. KEY FINDINGS AND LIMITATIONS: A total of 350 patients underwent randomisation, and 276 patients were histologically confirmed to have NMIBC. At 1 yr, 31 patients in the ERBT group and 46 in the SR group developed recurrence; the Kaplan-Meier estimate of 1- yr recurrence rates were 29% (95% confidence interval, 18-37) in the ERBT group and 38% (95% confidence interval, 28-46) in the SR group (p = 0.007). Upon a subgroup analysis, patients with 1-3 cm tumour, single tumour, Ta disease, or intermediate-risk NMIBC had a significant benefit from ERBT. None of the patients in the ERBT group and three patients in the SR group developed progression to muscle-invasive bladder cancer; the Kaplan-Meier estimates of 1-yr progression rates were 0% in the ERBT group and 2.6% (95% confidence interval, 0-5.5) in the SR group (p = 0.065). The median operative time was 28 min (interquartile range, 20-45) in the ERBT group and 22 min (interquartile range, 15-30) in the SR group (p < 0.001). All other secondary outcomes were similar in the two groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: In patients with NMIBC of ≤ 3cm, ERBT resulted in a significant reduction in the 1-yr recurrence rate when compared with SR. The study results support ERBT as the first-line surgical treatment for patients with bladder tumours of≤ 3cm.
引用
- Teoh JY, Cheng CH, Tsang CF, et al. Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial. Eur Urol. 2024. PMID: 38692956. doi:10.1016/j.eururo.2024.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。